Your browser doesn't support javascript.
loading
The cumulative burden of self-reported, clinically relevant outcomes in long-term childhood cancer survivors and implications for survivorship care: A DCCSS LATER study.
Streefkerk, Nina; Teepen, Jop C; Feijen, Elizabeth A M; Józwiak, Katarzyna; van der Pal, Helena J H; Ronckers, Cecile M; De Vries, Andrica C H; Van der Heiden-van Der Loo, Margriet; Hollema, Nynke; van den Berg, Marleen; Loonen, Jacqueline; Grootenhuis, Martha A; Bresters, Dorine; Versluys, A Brigitta; van Dulmen-den Broeder, Eline; van den Heuvel-Eibrink, Marry M; van Leeuwen, Flora E; Neggers, Sebastian J C M M; Van Santen, Hanneke M; Hawkins, Mike; Hauptmann, Michael; Yoneoka, Daisuke; Korevaar, Joke C; Tissing, Wim J E; Kremer, Leontien C M.
Afiliação
  • Streefkerk N; Department Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Teepen JC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Feijen EAM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Józwiak K; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van der Pal HJH; Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ronckers CM; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
  • De Vries ACH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Van der Heiden-van Der Loo M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Hollema N; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
  • van den Berg M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Loonen J; Department of Pediatric Oncology/Hematology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, The Netherlands.
  • Grootenhuis MA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Bresters D; Department of Anesthesiology, Intensive Care and Pain Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Versluys AB; Department of Pediatric Oncology/Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • van Dulmen-den Broeder E; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van Leeuwen FE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Neggers SJCMM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Van Santen HM; Department of Pediatric Oncology/Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Hawkins M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Hauptmann M; Department of Pediatric Oncology/Hematology, Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, The Netherlands.
  • Yoneoka D; Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Korevaar JC; Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kremer LCM; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands.
Cancer ; 130(8): 1349-1358, 2024 Apr 15.
Article em En | MEDLINE | ID: mdl-38100618
ABSTRACT

BACKGROUND:

The aim of this study is to evaluate how cumulative burden of clinically relevant, self-reported outcomes in childhood cancer survivors (CCSs) compares to a sibling control group and to explore how the burden corresponds to levels of care proposed by existing risk stratifications.

METHODS:

The authors invited 5925 5-year survivors from the Dutch Childhood Cancer Survivor Study (DCCSS LATER) cohort and their 1066 siblings to complete a questionnaire on health outcomes. Health outcomes were validated by self-reported medication use or medical record review. Missing data on clinically relevant outcomes in CCSs for whom no questionnaire data were available were imputed with predictive mean matching. We calculated the mean cumulative count (MCC) for clinically relevant outcomes. Furthermore, we calculated 30-year MCC for groups of CCSs based on primary cancer diagnosis and treatment, ranked 30-year MCC, and compared the ranking to levels of care according to existing risk stratifications.

RESULTS:

At median 18.5 years after 5-year survival, 46% of CCSs had at least one clinically relevant outcome. CCSs experienced 2.8 times more health conditions than siblings (30-year MCC = 0.79; 95% confidence interval [CI], 0.74-0.85 vs. 30-year MCC = 0.29; 95% CI, 0.25-0.34). CCSs' burden of clinically relevant outcomes consisted mainly of endocrine and vascular conditions and varied by primary cancer type. The ranking of the 30-year MCC often did not correspond with levels of care in existing risk stratifications.

CONCLUSIONS:

CCSs experience a high cumulative burden of clinically relevant outcomes that was not completely reflected by current risk stratifications. Choices for survivorship care should extend beyond primary tumor and treatment parameters, and should consider also including CCSs' current morbidity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sobreviventes de Câncer / Neoplasias Limite: Child / Humans Idioma: En Revista: Cancer Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sobreviventes de Câncer / Neoplasias Limite: Child / Humans Idioma: En Revista: Cancer Ano de publicação: 2024 Tipo de documento: Article